July 25, 2019

Grassley Statement on Committee Passage of Prescription Drug Pricing Reduction Act

Washington – Senate Finance Committee Chairman Chuck Grassley
(R-Iowa) released the following statement on the broad, bipartisan passage of
the Prescription
Drug Pricing Reduction Act
, which he co-authored with Ranking Member Ron
Wyden (D-Ore.). The bill passed out of committee by a 19-9 vote.

 

“The broad,
bipartisan passage of the Prescription Drug Pricing Reduction Act out of the
Senate Finance Committee is the first step toward fulfilling a promise that
we’ve all made to the American people – lowering prescription drug prices. I’d
like to thank Ranking Member Wyden for his partnership on this legislation, and
my colleagues on the committee who have contributed to this effort. I also want
to thank President Trump and Secretary Azar for their endorsement of our
legislation.

 

“Everyone
can agree that the price of many prescription drugs is too high. These
skyrocketing costs hurt seniors, lower-income earners, people with disabilities
and all Americans. This legislation is the result of months of working across
the aisle to find areas of consensus. Its commonsense reforms will save more
than $100 billion and deliver real relief to patients across the board while
preserving innovation in the health care industry.

 

“The Senate
is making important moves to improve our nation’s health care system. In addition
to the bipartisan legislation our committee passed today, there are good
policies coming from the Senate Judiciary and HELP Committees as well. This is
the kind of bipartisan action necessary to enact real reforms that will benefit
patients and taxpayers.

 

“Americans
are demanding action to reduce prescription drug prices. It’s past time we take
it. I hope we can bring this important health care reform legislation to a vote
this fall and finally give patients the relief they need and deserve.”

 

Congressional Budget Office (CBO) Score:

 

  • ·        
    Taxpayers save $85 billion in Medicare: The combination of the
    Part D redesign and the inflation-rebate policies would save Medicare
    approximately $85 billion over the 2019-2029 period ($35 billion and $50
    billion, respectively).

 

  • ·        
    Beneficiaries save $27 billion in out-of-pocket
    costs
    :
    The combination of the two policies would reduce beneficiaries’ spending for
    cost-sharing, also known as out-of-pocket expenses, by approximately $27
    billion over the same 10-year period ($20 billion and $7 billion,
    respectively).

 

  • ·        
    Beneficiaries save $5 billion in premiums: The combination of the
    two policies would reduce beneficiaries’ spending on premiums by approximately
    $5 billion over the same 10-year period ($1 billion and $4 billion,
    respectively).

 

  • ·        
    Taxpayers save $15 billion in Medicaid: Clarifying how prices
    are calculated and increasing the maximum rebate amount in Medicaid save the
    federal government approximately $15 billion.

 

  • ·        Americans in the commercial market would see savings: The inflation-rebate
    provision would reduce costs for prescription drug benefits offered by
    commercial insurance plans and the redesign provision would not have a
    substantial effect on prescription drug benefits offered by commercial
    insurance plans. 

 

Details
of the legislation can be found below. Text of the chairman’s mark can be
found HERE.
Modifications to the chairman’s mark can be found HERE.
Endorsements of the legislation can be found HERE
and HERE.

 

Medicare:

  • ·        
    Modernize
    and improve the successful Part D program by:

o  
Simplifying
the program’s design;

o  
Protecting
beneficiaries with high costs and providing peace of mind through an on
out-of-pocket spending cap;

o  
Improving
incentives to increase negotiation between prescription drug plans and
manufacturers;

o  
Protecting
the program from rampant manufacturer drug price increases; and

o  
Benefiting
patients and taxpayers through lower government spending, premiums, and out-of-pocket
costs.

  • ·        
    Increase
    transparency into pharmacy benefit manager (PBM) practices and manufacturer
    drug pricing decisions;
  • ·        Improve
    how Medicare calculates Part B prescription drug payment amounts to lower
    spending and beneficiary out-of-pocket costs; and

·        
Eliminate
excess Part B drug payments that drive up beneficiary and program costs.

 

Medicaid:

  • ·        
    Increase
    transparency and make manufacturers more accountable to federal taxpayers;
  • ·        
    Allow
    Medicaid to pay for gene therapies for rare disease through new risk-sharing
    value-based agreements, which will increase access to life-saving, miracle
    treatments for the most vulnerable;
  • ·        
    Apply
    pressure on manufacturers to lower list prices and report more accurate
    calculations of their rebate obligations; and
  • ·        
    Prevent
    spread pricing and gaming in the Medicaid program by PBMs to ensure that
    beneficiaries, states and the federal government are getting the best deal
    possible.
Print 
Email 
Share 
Share